Alnylam Canada ULC – Receives Positive Recommendation From Canada’s Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (Vutrisiran Injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

Why It Matters

Public funding unlocks access to the first‑in‑class RNAi therapy for ATTR‑CM, potentially extending survival and reshaping the treatment landscape for a disease with limited options.

Key Takeaways

• CDA recommends public reimbursement for AMVUTTRA in ATTR‑CM
• HELIOS‑B trial met all primary and secondary endpoints
• Quarterly subcutaneous injection targets both wild‑type and variant TTR
• Expected to extend survival beyond current 2‑5 year prognosis
• Expands Alnylam’s RNAi portfolio in over 15 countries

Pulse Analysis

ATTR‑CM remains a rare but devastating form of heart disease, characterized by misfolded transthyretin deposits that impair cardiac function and limit life expectancy to two to five years after diagnosis. Early detection is challenging, and existing therapies largely manage symptoms rather than the underlying protein aggregation. This clinical void has driven intense research into disease‑modifying approaches, positioning RNA interference as a promising avenue to silence the TTR gene at its source.

AMVUTTRA® (vutrisiran) leverages Alnylam’s siRNA platform to degrade both wild‑type and mutant TTR messenger RNA, reducing amyloid formation and halting disease progression. The multinational HELIOS‑B Phase 3 study enrolled patients with either hereditary or wild‑type ATTR‑CM and achieved statistically significant reductions in all‑cause mortality, cardiovascular events, and improvements in six‑minute walk distance, NYHA class, and quality‑of‑life scores. These outcomes differentiate AMVUTTRA® from conventional TTR stabilizers, offering a mechanistic breakthrough that directly addresses the genetic driver of amyloidosis.

The CDA’s positive reimbursement recommendation signals a pivotal shift for Canadian patients, aligning public coverage with a therapy that could substantially extend survival and improve daily functioning. For Alnylam, the decision unlocks a new revenue stream in a market eager for innovative treatments, reinforcing its leadership in RNAi therapeutics. Moreover, the approval may accelerate adoption of gene‑silencing modalities across other protein‑misfolding disorders, cementing RNA interference as a cornerstone of next‑generation precision medicine.